logo
logo
Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc.

NASDAQ•ARQT
CEO: Mr. Todd Franklin Watanabe M.A.
セクター: Healthcare
業種: Biotechnology
上場日: 2020-01-31
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
連絡先情報
3027 Townsgate Road, Suite 300, Westlake Village, CA, 91361, United States
805-418-5006
www.arcutis.com
時価総額
$3.27B
PER (TTM)
-76.9
33.3
配当利回り
--
52週高値
$31.77
52週安値
$11.55
52週レンジ
75%
順位61Top 91.5%
2.0
F-Score
改良版 Piotroski 分析
8年ファンダメンタル
弱い • 2 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$99.22M+121.69%
直近4四半期の推移

EPS

$0.06-118.18%
直近4四半期の推移

フリーCF

-$1.75M-94.96%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Q3 Profitability Achieved Net income $7.41M USD for the quarter, reversing $41.54M USD loss reported in Q3 2024.
Product Revenue Growth Strong Nine-month product revenue reached $244.57M USD, showing 152% growth over the comparable prior period.
ZORYVE 0.15% Sales Explode ZORYVE cream 0.15% product revenue grew 1686% YTD to $43.78M USD following US launch.
R&D Expenses Decreased Nine-month R&D expenses fell 9% to $56.60M USD due to completion of certain clinical studies.

リスク要因

Accumulated Deficit High Accumulated deficit reached $1.156B USD as of September 30, 2025, indicating ongoing operational burn.
Lease Liability Increased Lease amendment increased operating lease liability by $2.9M USD in Q3 2025 due to term extension.
Tax Law Uncertainty Poses Risk Potential US federal tax law changes, like the One Big Beautiful Bill Act, pose operational risks.
Reliance on Single Suppliers Reliance on single-source suppliers for manufacturing and clinical trial materials creates supply chain risk.

見通し

ARQ-234 Phase 1 Study Anticipate commencing Phase 1 study for ARQ-234 in atopic dermatitis during the first quarter of 2026.
ZORYVE Label Expansion Focus Expect continued R&D spend for ZORYVE label expansions and life cycle management moving forward.
Liquidity Sufficient Twelve Months Management believes existing capital resources cover projected operating requirements for at least 12 months.
SGA Expenses Expected Increase Selling, general, and administrative expenses expected to increase due to commercialization efforts for ZORYVE.

同業比較

売上高 (TTM)

Legend Biotech CorporationLEGN
$908.96M
+74.7%
Amicus Therapeutics, Inc.FOLD
$598.70M
+21.3%
Catalyst Pharmaceuticals, Inc.CPRX
$578.20M
+25.6%

粗利益率 (最新四半期)

IDEAYA Biosciences, Inc.IDYA
99.5%
+0.0pp
Travere Therapeutics, Inc.TVTX
99.0%
+1.6pp
Arcutis Biotherapeutics, Inc.ARQT
91.2%
+3.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
IBRX$6.52B-18.062.8%0.0%
CELC$4.85B-28.9-179.0%67.3%
FOLD$4.50B-314.4-6.8%51.0%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
11.6%
安定成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月24日
|
EPS:$0.02
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月28日|
    売上高: $99.22M+121.7%
    |
    EPS: $0.06-118.2%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $81.50M+164.1%
    |
    EPS: $-0.13-69.0%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $65.85M+32.8%
    |
    EPS: $-0.20-37.5%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月25日|
    売上高: $196.54M+229.7%
    |
    EPS: $-1.16+69.3%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $44.76M+17.4%
    |
    EPS: $-0.33-54.8%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月14日|
    売上高: $30.86M+494.6%
    |
    EPS: $-0.42-63.8%
    予想を上回る

  • Form 10-Q/A - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年7月24日|
    売上高: $49.57M+1682.4%
    |
    EPS: $-0.32-75.4%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月14日|修正版データを参照